Helix BioPharma Corp. Announces Delay of Annual Filings

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced today that it anticipates the filing of its annual financial statements, management’s discussion and analysis, annual information form and related officer certifications for the financial year ended July 31, 2021 (collectively, the …

Helix BioPharma Corp. Announces Appointment of Interim Chief Executive Officer

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company’s Chairman of the Board, Prof. Dr. Slawomir Majewski, will immediately assume the role of Interim CEO while the Company continues to identify and evaluate candidates.

Helix BioPharma Corp. Announces Appointment of New Director

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno- oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr. Krzysztof Saczek has been appointed as a member of the Board of Directors of the Company effective immediately.

Helix BioPharma Corp. Announces Changes to the Company’s Board of Directors and Management

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Heman Chao has notified the Board of Directors of the Company of his intention to step down from the position of Chief Executive Officer (“CEO”), Chief Scientific Officer (“CSO”) and …

Helix BioPharma Corp. Announces Appointment of New Auditor and Extends Period to Exercise Warrants

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has appointed Marcum LLP as the Company’s new auditor, replacing BDO Canada LLP. The Company has filed a Notice of Change of Auditor in respect of this change under …

Helix Biopharma Corp. Announces Fiscal Third Quarter 2021 Results

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal third quarter ended April 30, 2021.

Helix BioPharma Corp. Announces Closing of First Tranche of Institutional Investment for Gross Proceeds of CAD$3.5 million

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has closed the first tranche of the previously announced private placement pursuant to the convertible security funding agreement (the “Agreement”) with Lind Global Macro Fund, LP, a New York based …

Helix BioPharma Corp. Announces Institutional Investment for Gross Proceeds of up to CAD$10 million

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive convertible security funding agreement (the “Agreement”) with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC …

Helix BioPharma Corp. Extends Period to Exercise Warrants

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immunooncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to extend the exercise period of a total of 2,837,000 outstanding common share purchase warrants (the “Warrants”), …